Latest News and Press Releases
Want to stay updated on the latest news?
-
Regulated information — Inside information May 28, 2020 Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep...
-
Regulated information — Inside information May 26, 2020 Breda, the Netherlands / Ghent, Belgium — argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep...
-
Regulated information – Inside information Trial met primary endpoint (p ˂0.0001) Well-tolerated; safety profile comparable to placebo Biologics License Application on track to be submitted to...
-
- Topline data readout from Phase 3 ADAPT trial of efgartigimod in generalized myasthenia gravis on track for mid-2020 and Biologics License Application filing by end of year...
-
Topline data from Phase 3 ADAPT trial of efgartigimod in gMG expected in mid-2020Continued progress across broadest FcRn antagonist pipeline with up to five Phase 3 trials to be...
-
Regulated information – Inside information November 12, 2019 - 10:00 PM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX) a clinical-stage biotechnology company...
-
Regulated information – Inside information November 8, 2019, 7:00 AM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company...
-
Regulated information – Inside information November 6, 2019, 10:45 PM ESTNovember 7, 2019, 04:45 AM CET Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a...
-
Enrollment on track for Phase 3 ADAPT trial of efgartigimod in gMG patients with topline results expected in 2H20Two efgartigimod trial initiations expected in 4Q19: Phase 2 proof-of-concept...
-
September 3, 2019 Breda, the Netherlands / Ghent, Belgium – argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based...